Here's the short version. The cited evidence does not establish a safe or effective tesamorelin stack. The linked PubMed search for tesamorelin with sermorelin, CJC-1295, ipamorelin, retatrutide, AOD-9604 or somatropin is a starting point for checking combination research, rather than proof that every possible study has been ruled out [14]. What you can know is what each drug is, what the label warns, and whether the partner drug is even legal to prescribe.
| Pair | Studied together? | Same signal? | Status of the partner drug (US) |
|---|---|---|---|
| Tesamorelin + sermorelin | Not established in cited evidence | Yes, both copy GHRH | Sermorelin: from compounding pharmacies; former brand Geref withdrawn in 2009, not for safety reasons |
| Tesamorelin + CJC-1295 | Not established in cited evidence | Yes, CJC-1295 is a GHRH analog | Never approved; FDA's compounding advisers voted against it (December 4, 2024) |
| Tesamorelin + CJC-1295 + ipamorelin | Not established in cited evidence | Partly | Neither partner approved; ipamorelin vote 0-12, 1 abstention (October 29, 2024) |
| Tesamorelin + ipamorelin | Not established in cited evidence | No, ipamorelin acts on the ghrelin receptor | Never approved; covered on our tesamorelin and ipamorelin page |
| Tesamorelin + retatrutide | Not established in cited evidence | No, retatrutide acts on GLP-1, GIP and glucagon receptors | Investigational; FDA says it can't be used in compounding |
| Tesamorelin + growth hormone | Not established in cited evidence | Downstream of the same signal | Growth hormone is FDA-approved for its own labeled uses |
GHRH is growth-hormone-releasing hormone, the brain's signal for the pituitary to release growth hormone.
What tesamorelin is, in one paragraph
Tesamorelin is a lab-made version of growth-hormone-releasing hormone, built on the hormone's full 44-amino-acid sequence with a small chemical chain added [1]. It's approved as Egrifta SV and Egrifta WR to reduce excess abdominal fat in adults with HIV-associated lipodystrophy [1] [2].
Since March 23, 2020, FDA has regulated it as a biologic, and biologics aren't eligible for the 503A and 503B compounding exemptions [3] [4]. In plain terms, a compounding pharmacy can't legally make it.
The label's limits matter here too. Long-term heart safety hasn't been established. It "is not indicated for weight loss management as it has a weight neutral effect" [1].
For how people get it, see tesamorelin's legal status.
Tesamorelin and sermorelin
Both mimic GHRH. Sharing a signaling pathway does not establish the safety or benefit of giving them together.
Are they the same drug? No. Sermorelin is a copy of just the first 29 amino acids of GHRH. Tesamorelin uses all 44, plus a small chemical chain attached at one end [1].
Their status is different too. Sermorelin was approved as Geref until the maker stopped selling it. FDA withdrew the approvals in 2009 and later said that wasn't for safety or effectiveness reasons [5]. Today it comes from compounding pharmacies. Tesamorelin is brand-only.
Both raise growth hormone and IGF-1. The Egrifta label already tells prescribers to monitor IGF-1 because the effects of long-term elevation are unknown [1]. Adding a second GHRH drug pushes on that same number.
Tesamorelin and CJC-1295 (with or without ipamorelin)
CJC-1295 is another GHRH analog that has never been approved. FDA's compounding advisers voted against it in December 2024, and the cited evidence does not establish a safe, effective or lawful ordinary compounded pairing.
At the December 4, 2024 meeting, the committee voted 12 to 1 against listing CJC-1295 acetate for compounding, and 13 to 0 against each of its other four forms [6]. FDA's own safety page lists serious adverse events with CJC-1295, including a faster heart rate and a whole-body flushing reaction [8].
Is tesamorelin the same as CJC-1295? No. Both mimic GHRH, but they're different molecules, and only tesamorelin is an approved drug. Adding ipamorelin doesn't change the picture: it was voted down too (next section). The legal side of the pair is covered in ipamorelin and CJC-1295's legal status.
Tesamorelin and ipamorelin
Ipamorelin works through a different receptor, the one ghrelin uses, and it has never been approved. At the October 29, 2024 meeting, FDA's compounding advisers voted 0 to 12, with one abstention, against listing either form [7].
This pairing has its own page: tesamorelin and ipamorelin together.
Tesamorelin and retatrutide
Retatrutide is an investigational drug with no FDA approval, and FDA says it can't be used in compounding, so an online seller cannot establish an approved or lawful compounded regimen merely by offering a combination [9].
It isn't on FDA's list of 2026 novel drug approvals [10]. In its first large phase 3 trial, average weight loss reached 25.0% at 80 weeks on the highest dose tested, against 3.9% on placebo [11]. Lilly funded the study. That's a result for retatrutide alone. It does not establish a benefit alongside tesamorelin.
FDA has also warned sellers that market retatrutide as "research use only" while selling it for people [9]. Products like that are of unknown quality.
Tesamorelin and growth hormone (or AOD-9604, IGF-1 LR3)
Tesamorelin works by raising your own growth hormone and IGF-1. Adding growth hormone on top adds to the same signal the label already tells prescribers to watch.
The Egrifta label doesn't address use with growth hormone or other growth-hormone boosters at all [1]. What it does say: IGF-1 rose above the normal range in many people on tesamorelin. At 26 weeks, 47% had IGF-1 more than two standard deviations above average, and 36% more than three [1]. Growth hormone itself is approved for its own labeled uses and needs its own prescription.
AOD-9604 has never been FDA-approved. FDA lists safety concerns for compounded forms, including possible immune reactions and serious adverse events whose cause isn't clear [8]. IGF-1 LR3 isn't an FDA-approved drug either. The cited evidence does not establish either pairing with tesamorelin.
What the Egrifta label warns about
The label's warnings section has seven parts, and combination use needs review rather than an assumption of safety [1]:
- Neoplasms: a possible increased risk of tumors. Any past cancer should be inactive and its treatment finished first.
- Elevated IGF-1: the effects of long-term elevation are unknown, so IGF-1 is monitored.
- Fluid retention: swelling, joint pain and carpal tunnel syndrome.
- Glucose intolerance or diabetes: HbA1c reached 6.5% or more in 5% of people on tesamorelin, against 1% on placebo, by week 26.
- Hypersensitivity reactions: in 4% of people in trials, including itching, redness, flushing, hives and rash.
- Injection-site reactions: 25% on tesamorelin against 14% on placebo in the first 26 weeks.
- Acute critical illness: higher death rates have been reported when critically ill patients were given growth hormone.
The label also says not to use it with a disrupted hypothalamic-pituitary axis, with active cancer, with a known allergy to it, or in pregnancy [1].
Drug interactions on the label
The label says growth hormone can change how the liver clears drugs processed by CYP450 enzymes. People on glucocorticoid replacement may need a dose change after starting tesamorelin [1].
The CYP450 list includes corticosteroids, sex steroids, seizure medicines and cyclosporine. One tested pairing, with the cholesterol drug simvastatin, showed no meaningful effect on simvastatin levels [1]. Your prescriber adjusts any of this; it's a reason to tell them about every medicine and supplement you take.
If belly fat or body composition is the goal
For people without HIV-associated lipodystrophy, tesamorelin isn't the labeled option; prescribers have other routes.
In the trials it was approved on, tesamorelin cut deep belly fat by about 15% over 26 weeks while it rose on placebo, without shrinking fat under the skin [12] [13]. Those were adults with HIV. Those pivotal results do not establish a benefit for healthy adults or alongside these other treatments.
Related questions have their own pages: does tesamorelin build muscle, does tesamorelin increase testosterone, does tesamorelin affect appetite and how long tesamorelin takes to work. For goals with approved options, start with the metabolic shortlist or the body composition shortlist.